The potential for IPIX has been great and continue
Post# of 72439
(Total Views: 401)
Posted On: 07/31/2019 7:06:40 AM
The potential for IPIX has been great and continues to grow.
Financing is coming on line and I'm thinking we'll see a partner or a license for brilacidin OM in the next couple months, if not, then very shortly after.
This first clinical trial, evaluating Brilacidin in oral tablet form, is targeted to commence later this year or early thereafter.
Since IPIX is ALL retail (behind the scenes we don't know if we're really all retail or not) it's up to us to be our own analysts of the science and judge of character of a company listed on the OTC. Transparency is one of the main keys involved in this.
Equally important, we can now dedicate further internal resources to moving our clinical portfolio ahead—developing novel oral medications for hard-to-treat diseases like IBD, Oral Mucositis and Cancer.
As we move forward, I think those challenging Leo and in part, Dr. B, will be set straight. Only a couple things I'd like to see and it can be in a filing right before they uplist.
And if all goes well with UP/UPS and the OM trial, this could happen by the end of next year.
IMO of course.
Getting more attention across many lines of science. Thinking some deep pockets will be keeping a closer eye on this little bio.
Financing is coming on line and I'm thinking we'll see a partner or a license for brilacidin OM in the next couple months, if not, then very shortly after.
This first clinical trial, evaluating Brilacidin in oral tablet form, is targeted to commence later this year or early thereafter.
Since IPIX is ALL retail (behind the scenes we don't know if we're really all retail or not) it's up to us to be our own analysts of the science and judge of character of a company listed on the OTC. Transparency is one of the main keys involved in this.
Equally important, we can now dedicate further internal resources to moving our clinical portfolio ahead—developing novel oral medications for hard-to-treat diseases like IBD, Oral Mucositis and Cancer.
As we move forward, I think those challenging Leo and in part, Dr. B, will be set straight. Only a couple things I'd like to see and it can be in a filing right before they uplist.
And if all goes well with UP/UPS and the OM trial, this could happen by the end of next year.
IMO of course.
Quote:
Is this study the University of Bologna that IPIX PRd about a long time ago? If so, seems like additional validation for Leo that K is still very much on the table.....I also note this altmetric score below. Not sure what it means, but it appears legitimate.
"Attn Score" for published (06/2019) Kevetrin AML Study
Quote:
Altmetric has tracked 13,294,961 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
Getting more attention across many lines of science. Thinking some deep pockets will be keeping a closer eye on this little bio.
(4)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼